Multifetal Reduction

Although not all multifetal pregnancies occur after the use of assisted reproductive technology, fertility treatments have contributed significantly to the increase in multifetal pregnancies. In almost all cases, it is preferable to avoid the risk of higher-order multifetal pregnancy by limiting the number of embryos to be transferred or by cancelling a gonadotropin cycle when the ovarian response suggests a high risk of a multifetal pregnancy.

Who should have a Fetal Anomaly Scan and why?

All women, whatever their age, have a small chance of delivering a baby with structural abnormalities that cause physical or mental limitation. Many such abnormalities can be diagnosed and ruled out with the fetal anomaly scan.

What might be seen?

Most serious abnormalities can be detected on a scan. However, it is not possible to see all problems. Some conditions such as cerebral palsy and autism will never be seen on a scan. The quality of imaging depends on many factors, including the position of the baby and the size of the mother.

Multifetal pregnancy reduction is defined as a first-trimester or early second-trimester procedure for reducing the total number of fetuses in a multifetal pregnancy by one or more . In most cases, the involved gestations will be higher-order multifetal pregnancies, defined by the presence of three or more fetuses. Throughout the document, multifetal pregnancy reduction is used to refer to reduction of a higher-order multifetal pregnancy by one or more fetuses.

For endocrine problems

Drug discovery and drug development are complex and expensive endeavors undertaken by pharmaceutical companies, academic scientists, and governments. As a result of this complex path from discovery to commercialization, partnering has become a standard practice for advancing drug candidates through development pipelines. Governments generally regulate what drugs can be marketed, how drugs are marketed, and in some jurisdictions,

For the digestive system

Drug discovery and drug development are complex and expensive endeavors undertaken by pharmaceutical companies, academic scientists, and governments. As a result of this complex path from discovery to commercialization, partnering has become a standard practice for advancing drug candidates through development pipelines. Governments generally regulate what drugs can be marketed, how drugs are marketed, and in some jurisdictions,

For the ear, nose and oropharynx

Drug discovery and drug development are complex and expensive endeavors undertaken by pharmaceutical companies, academic scientists, and governments. As a result of this complex path from discovery to commercialization, partnering has become a standard practice for advancing drug candidates through development pipelines. Governments generally regulate what drugs can be marketed, how drugs are marketed, and in some jurisdictions,

For the respiratory system

Drug discovery and drug development are complex and expensive endeavors undertaken by pharmaceutical companies, academic scientists, and governments. As a result of this complex path from discovery to commercialization, partnering has become a standard practice for advancing drug candidates through development pipelines. Governments generally regulate what drugs can be marketed, how drugs are marketed, and in some jurisdictions,

Make an appointment

We will send you a confirmation within 24 hours. Emergency? Call 1-2554-2356-33

Although pulmonary medicine only began to evolve as a medical specialty in the 1950s, William Welch and William Osler founded the ‘parent’ organization of the American Thoracic Society, the National Association.